iSpecimen Stock Forecast, Price & News

-0.45 (-7.32 %)
(As of 08/4/2021 12:00 AM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume115,046 shs
Average Volume685,177 shs
Market Capitalization$37.00 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ISPC News and Ratings via Email

Sign-up to receive the latest news and ratings for iSpecimen and its competitors with MarketBeat's FREE daily newsletter.

About iSpecimen

iSpecimen, Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables researchers to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.00 out of 5 stars

Medical Sector

1283rd out of 1,311 stocks

Commercial Physical Research Industry

22nd out of 23 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

iSpecimen (NASDAQ:ISPC) Frequently Asked Questions

What stocks does MarketBeat like better than iSpecimen?

Wall Street analysts have given iSpecimen a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iSpecimen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is iSpecimen's next earnings date?

iSpecimen is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for iSpecimen

How can I listen to iSpecimen's earnings call?

iSpecimen will be holding an earnings conference call on Tuesday, August 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13721607".

Who are iSpecimen's key executives?

iSpecimen's management team includes the following people:
  • Dr. Christopher J. Ianelli Ph.D., M.D., Founder, Pres, CEO & Director
  • Ms. Tracy Wilson Curley, Chief Financial Officer (Age 59, Pay $253.44k)
  • Ms. Jill Mullan, COO, Treasurer, Sec. & Director (Age 56, Pay $230k)
  • Mr. Benjamin Bielak, Chief Information Officer (Age 52, Pay $220k)
  • Mr. Eric Langlois, Sr. VP of Sales & Bus. Devel.
  • Ms. Carly Lejnieks, Sr. Director of Marketing
  • Mr. David Wages M.D., Ph.D., Chief Medical Officer

Who are some of iSpecimen's key competitors?

When did iSpecimen IPO?

(ISPC) raised $20 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 2,200,000 shares at $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is iSpecimen's stock symbol?

iSpecimen trades on the NASDAQ under the ticker symbol "ISPC."

When did the company's quiet period expire?

iSpecimen's quiet period expired on Tuesday, July 27th. iSpecimen had issued 2,250,000 shares in its initial public offering on June 17th. The total size of the offering was $18,000,000 based on an initial share price of $8.00. During the company's quiet period, insiders and underwriters involved in the IPO were restricted from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of iSpecimen?

Shares of ISPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iSpecimen's stock price today?

One share of ISPC stock can currently be purchased for approximately $5.70.

How much money does iSpecimen make?

iSpecimen has a market capitalization of $37.00 million.

How many employees does iSpecimen have?

iSpecimen employs 46 workers across the globe.

What is iSpecimen's official website?

The official website for iSpecimen is

How can I contact iSpecimen?

The company can be reached via phone at 781 301 6700 or via email at [email protected]

This page was last updated on 8/5/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.